MX2018013663A - Metodos para tratar trastornos de sueño de ritmo circadiano. - Google Patents

Metodos para tratar trastornos de sueño de ritmo circadiano.

Info

Publication number
MX2018013663A
MX2018013663A MX2018013663A MX2018013663A MX2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A MX 2018013663 A MX2018013663 A MX 2018013663A
Authority
MX
Mexico
Prior art keywords
methods
sleep disorders
circadian rhythm
rhythm sleep
treating circadian
Prior art date
Application number
MX2018013663A
Other languages
English (en)
Inventor
Moline Margaret
T Beuckmann Carsten
Satlin Andrew
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018013663A publication Critical patent/MX2018013663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen métodos para tratar un trastorno de ritmo irregular de sueño-vigilia en sujetos y composiciones para el uso en los mismos.
MX2018013663A 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano. MX2018013663A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (1)

Publication Number Publication Date
MX2018013663A true MX2018013663A (es) 2019-07-18

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013663A MX2018013663A (es) 2016-05-12 2017-05-11 Metodos para tratar trastornos de sueño de ritmo circadiano.

Country Status (16)

Country Link
US (2) US11096941B2 (es)
EP (2) EP4056180A1 (es)
JP (2) JP6888026B2 (es)
KR (2) KR20230043227A (es)
CN (1) CN109640998A (es)
AU (2) AU2017264871B2 (es)
BR (1) BR112018073037A2 (es)
CA (1) CA3022068A1 (es)
ES (1) ES2904625T3 (es)
IL (2) IL291791A (es)
MX (1) MX2018013663A (es)
RU (1) RU2763493C2 (es)
SG (1) SG11201809527UA (es)
TW (1) TWI795359B (es)
WO (1) WO2017197160A1 (es)
ZA (1) ZA201807903B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230043227A (ko) * 2016-05-12 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 일주기 리듬 수면 장애를 치료하는 방법
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
EP3993801A4 (en) * 2019-09-13 2023-07-19 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INSOMNIA
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN117769423A (zh) * 2021-07-26 2024-03-26 卫材R&D管理有限公司 莱博雷生用于在治疗与神经系统变性疾病相关的不规律睡眠觉醒节律紊乱和昼夜节律性睡眠障碍的方法中使用
CN116421605A (zh) * 2022-01-04 2023-07-14 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
WO2024064897A1 (en) * 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082143A1 (en) 2004-02-20 2005-09-09 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EP2626350B1 (en) 2010-09-22 2015-04-15 Eisai R&D Management Co., Ltd. Cyclopropane compound
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
SG11201703064WA (en) * 2014-10-23 2017-05-30 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
KR20230043227A (ko) * 2016-05-12 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 일주기 리듬 수면 장애를 치료하는 방법

Also Published As

Publication number Publication date
JP7150096B2 (ja) 2022-10-07
RU2763493C2 (ru) 2021-12-29
WO2017197160A1 (en) 2017-11-16
IL262803B (en) 2022-05-01
EP4056180A1 (en) 2022-09-14
AU2017264871B2 (en) 2023-03-16
IL291791A (en) 2022-06-01
AU2017264871A1 (en) 2018-11-15
RU2018143809A3 (es) 2020-09-17
JP6888026B2 (ja) 2021-06-16
ES2904625T3 (es) 2022-04-05
CA3022068A1 (en) 2017-11-16
JP2021120410A (ja) 2021-08-19
JP2019518732A (ja) 2019-07-04
IL262803A (en) 2018-12-31
EP3454859A1 (en) 2019-03-20
CN109640998A (zh) 2019-04-16
SG11201809527UA (en) 2018-11-29
KR20190013820A (ko) 2019-02-11
TWI795359B (zh) 2023-03-11
EP3454859B1 (en) 2021-12-01
BR112018073037A2 (pt) 2019-02-26
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
US20200179382A1 (en) 2020-06-11
KR102511855B1 (ko) 2023-03-20
RU2018143809A (ru) 2020-06-15
US11096941B2 (en) 2021-08-24
ZA201807903B (en) 2021-04-28
AU2023203418A1 (en) 2023-06-29
US20210353625A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12017500153B1 (en) Compositions and methods of use for treating metabolic disorders
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX364438B (es) Inhibidores covalentes de kras g12c.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2020007448A (es) Tratamiento de trastornos del ritmo circadiano.
MX2020012689A (es) Tratamiento de trastornos del ritmo circadiano.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
PH12019550033A1 (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
AR108472A1 (es) Métodos de tratamiento de los trastornos del ritmo circadiano del sueño
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
PH12020500645A1 (en) Treatment of disorders with tasimelteon
UA97357U (en) Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
MX2018007426A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y transtornos.